COMPANY ORIGIN
PBI is a clinical-stage biotechnology company founded in 2013 to develop first-in-class nucleic acid based immunotherapeutics through application of our proprietary molecular adjuvants and delivery platforms. The company is headquartered in Taipei, Taiwan, with a wholly owned U.S. subsidiary located in San Diego, CA, USA. PBI is led by seasoned business and technical executives and advised by a prestigious scientific advisory board with deep experience in the development and clinical evaluation of immunotherapeutic interventions in relevant disease indications. PBI has used strategic licensing and acquisition efforts to assemble a robust portfolio of vaccine, adjuvant, and delivery technologies that enable induction of robust antigen specific T cell responses against pathogen and tumor-associated targets.
In order to facilitate rapid and cost-effective deployment of PBI technology, the company’s development strategy comprises an initial focus on immunotherapeutic candidates targeting well characterized antigens in disease indications eligible for orphan product and breakthrough technology designations. Towards this end, PBI’s initial clinical development have focused on products to treat persistent human papillomavirus (HPV) infections and related cancers where the target antigens are well defined (HPV E6/E7), there are clear clinical endpoints, FDA-approved screening tests, and a favorable pathway to regulatory approval. Successful demonstration of clinical activity in these initial indications will provide the foundation of an HPV immunotherapy franchise. Supported by this foundation, we plan to deploy core PBI technologies to target other cancers and chronic viral infections where the induction of potent antigen specific immunological responses is expected to improve clinical outcome.
At its inception, PBI carefully built a functional structure based on expert consultants and had employed only essential personnel and used service contractors for operations to preserve its limited resources. We have now moved beyond this model. Currently, we have recruited in-house a highly qualified team of industry experts who are dedicated full-time to propelling the company forward. The organization chart shown below indicates the structure we continue to build on, followed by descriptions of key positions/structures that are currently filled.
